The Drug Company That Shocked the World with Its Prices Dodged $10 Billion in Taxes, Report Says
July 13, 2016
(The Washington Post) – Over the last few years, Gilead Sciences has grown into one of the world’s largest pharmaceutical companies, fueled by the sales of expensive specialty treatments for hepatitis C. The company’s revenue has tripled since 2012, to $32.6 billion last year. According to a report to be released Wednesday, Gilead has also developed another specialty: Avoiding billions in taxes.